Electra Therapeutics raised $350 million in an upsized IPO to advance precision immune therapies, according to the company’s financing update. The proceeds are earmarked to support development of Electra’s lead program for secondary hemophagocytic lymphohistiocytosis, a severe hyperinflammatory condition with limited targeted treatment options. The fundraising reinforces investor appetite for immunology programs positioned as mechanism-driven rather than broad immunosuppression. It also underscores the market’s continued willingness to fund companies building near-term clinical pathways. With the IPO cash secured, Electra can extend program execution across preclinical-to-clinical translation and potential expansion of its pipeline strategy.